Thromboprophylaxis in immobilized medical patients

European Journal of Medical Research

Volumn 9, Issue 3, 2004, Pages 131-134

  Vaitkus, Paul T ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Dalteparin; Deep vein thrombosis; Enoxaparin; Prophylaxis low molecular weight heparin; Pulmonary embolism; Venous thromboembolism

Indexed keywords

ANTICOAGULANT AGENT; LOW MOLECULAR WEIGHT HEPARIN;

CLINICAL TRIAL; HUMAN; IMMOBILIZATION; REVIEW; VEIN THROMBOSIS;

ANTICOAGULANTS; CLINICAL TRIALS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; IMMOBILIZATION; VENOUS THROMBOSIS;

EID: 4644262805     PISSN: 09492321     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (24)

1. Wood KE (2002) Major pulmonary embolism: review of a pathophysiologic approach to the golden hour of hemodynamically significant pulmonary embolism. Chest 121: 877-905
2. Barritt DW, Jordan SC (1960) Anticoagulant drugs in the treatment of pulmonary embolism: a controlled trial. Lancet 1: 1309-1312
3. Goldhaber SZ (2002) Related Articles, Links Thrombolysis for pulmonary embolism N Engl J Med 347: 1131-1132
4. Konstantinides S, Geibel A, Heusel G, Heinrich F, Kasper W (2002) Management Strategies and Prognosis of Pulmonary Embolism-3 Trial Investigators. Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism. N Engl J Med 347: 1143-1150
5. Morgan R, Belli AM (2002) Percutaneous thrombectomy: a review. Eur Radiol 12: 205-217
6. Horlander KT, Mannino DM, Leeper KV (2003) Pulmonary embolism mortality in the United States, 1979-1998: an analysis using multiple-cause mortality data. Arch Intern Med 163: 1711-1717
7. Ageno W, Turpie AG (2002) Deep venous thrombosis in the medically ill. Curr Hematol Rep 1: 73-78
8. Cohen AT (2002) Discoveries in thrombosis care for medical patients. Semin Thromb Hemost 28 Suppl 3: 13-17
9. Ageno W, Squizzato A, Ambrosini F, Dentali F, Marchesi C, Mera V, Steidl L, Venco A (2002) Thrombosis prophylaxis in medical patients: a retrospective review of clinical practice patterns. Haematologica 87: 746-750
10. Samama MM, Cohen AT, Darmon JY, Desjardins L, Eldor A, Janbon C, Leizorovicz A, Nguyen H, Olsson, CG, Turpie AG, Weisslinger N (1999) A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med 341: 793-800
11. Vaitkus PT, Leizorovicz, A, Goldhaber SZ, PREVENT Investigator Group, (2002) Rationale and design of a clinical trial of a low-molecular-weight heparin in preventing clinically important venous thromboembolism in medical patients: the prospective evaluation of dalteparin efficacy for prevention of venous thromboembolism in immobilized patients trial (the PREVENT study). Vasc Med7: 269-273
12. Halkin H, Goldberg J, Modan M, Modan B (1982) Reduction of mortality in general medical in-patients by low-dose heparin prophylaxis. Ann Intern Med 96: 561-565
13. Leizorovicz A (2003) Results of the prospective evaluation of dalteparin efficacy for prevention of venous thromboembolism in immobilized patients trial (PREVENT) presented at Society of Critical Care Medicine. January 31, 2003, San Antonio, TX
14. Geerts W, Cook D, Selby R, Etchells E (2002) Venous thromboembolism and its prevention in critical care. J Crit Care 17: 95-104
15. Cohen AT (2000) Venous thromboembolic disease management of the nonsurgical moderate- and high-risk patient. Semin Hematl 37 (Suppl 5): 19-22
16. Anderson FA Jr, Spencer FA (2003) Risk factors for venous thromboembolism. Circulation 107(Suppl 1): 19-16
17. Mismetti P, Laporte-Simitsidis S, Tardy B, Cucherat M, Buchmuller A, Juillard-Delsart D, Decousus H (2000) Prevention of venous thromboembolism in internal medicine with unfractionated or low-molecular-weight heparins: a meta-analysis od randomised clinical trials. Thromb Haemost 83: 14-19
18. Kearon C, Julian JA, Math M, Newman TE, Ginsberg JS (1998) Noninvasive Diagnosis of Deep Venous Thrombosis. Ann Intern Med 128: 663-677
19. Stein PD, Hull RD, Patel KC, Olson RE, Ghali WA, Alshab AK, Meyers FA (2003) Venous Thromboembolic Disease: Comparison of the Diagnostic Process in Men and Women. Arch Intern Med 163: 1689-1694
20. Leizorovicz A, Kassai B. Becker F, Cucherat M (2003) The assessment of deep vein thromboses for therapeutic trials. Angiology 54: 19-24
21. Leizorovicz A, Cohen AT, Turpie AGG, Olsson CG, Vaitkus PT, Goldhaber SZ (2003) Thromboprophylaxis in Acutely I11 Medical Patients: A Randomized Placebo Controlled Trial of Dalteparin. Rev Esp Geriatr Gerontol 38(Supl 1): 113
22. Kucher N, Leizorovicz A, Cohen AT, Turpie AG, Olsson CG, Vaitkus PT, Goldhaber SZ (2004) Obesity does not attenuate the effectiveness of low-dose dalteparin in preventing venous thromboembolism in medically ill patients. (Abstract to be presented at American College of Cardiology)
23. Cohen AT, Leizorovicz A, Turpie AGG, Olsson CG, Vaitkus PT, Goldhaber SZ (2003) Thromboprophylaxis with Dalteparin for the Prevention of Venous Thromboembolism in Acutely I11 Medical Patients with Respiratory Failure. Chest 124: 1325-1335
24. Turpie AGG, Cohen AT, Olsson CG, Vaitkus PT, GoldhaberSZ, Leizorovicz A (2004) Thromboprophylaxis With Dalteparin Reduces Clinically Important Venous Thromboembolism in Patients With Congestive Heart Failure. (Abstract to be presented at American College of Cardiology)